Retatrutide vs Tirzepatide: Triple Agonism vs Dual Incretin Therapy Explained 

Introduction: A New Era in Weight Loss Medicine

The obesity drug market has changed fast. Just a few years ago, tirzepatide (Mounjaro / Zepbound) was the most effective weight loss drug ever approved. Then came retatrutide.

In December 2025, Eli Lilly released Phase 3 TRIUMPH-4 data. Retatrutide produced an average of 28.7% body weight loss at 68 weeks. That is the highest figure ever recorded in a Phase 3 obesity trial.

So how do these two drugs compare? The answer comes down to one extra hormone receptor. This article breaks down the science, the clinical data, and the practical differences in plain language.

What Are These Two Drugs? A Quick Profile

Tirzepatide: The FDA-Approved Dual Incretin

Eli Lilly makes Tirzepatide. It activates two gut hormone receptors at the same time: GLP-1 and GIP. Researchers call this two-receptor approach dual incretin therapy.

Two brand names sell it:

• Mounjaro: approved for type 2 diabetes (May 2022)
• Zepbound: approved for chronic weight management in obesity (November 2023)

You take it as a once-weekly injection under the skin. Researchers typically study doses in the 2.5 mg to 15 mg range. Available by prescription today in the US, EU, UK, and many other countries.

Retatrutide (LY3437943): The Investigational Triple Agonist

Eli Lilly also makes Retatrutide. It activates three hormone receptors: GLP-1, GIP, and the glucagon receptor. This triple-receptor approach is what makes it unique. No other approved drug does this.

It has no brand name yet. The drug is still investigational, meaning it is not FDA-approved. As of April 2026, it is in Phase 3 clinical trials under the TRIUMPH programme.

Like tirzepatide, it is a once-weekly injection. Trial doses range from 1 mg to 12 mg. The only legal way to access it right now is through a clinical trial or a licensed compounding pharmacy.

At a Glance: Retatrutide vs Tirzepatide

How They Work: Mechanism of Action Explained

The Shared Foundation: GLP-1 and GIP

Both drugs share the same base. They both activate GLP-1 and GIP receptors. Understanding what these do helps you see why these drugs are so effective.

GLP-1 receptor activation does several things at once. It delays gastric emptying, meaning food moves through the stomach more slowly. It also sends signals to the brain that help reduce appetite.

It helps the pancreas produce insulin when you eat food. And it lowers glucagon levels when blood sugar is high. As a result, overall food intake decreases, fullness occurs sooner, and blood glucose levels remain more stable. 

GIP receptor activation works alongside GLP-1. It further boosts insulin release.

It may help the body use insulin more effectively. It also influences how the body stores and uses fat. Together, GLP-1 and GIP produce a synergistic effect; each hormone makes the other work better.

This dual action is why tirzepatide outperforms older GLP-1-only drugs like semaglutide (Ozempic / Wegovy). In head-to-head data, tirzepatide produced significantly greater weight loss than semaglutide at comparable doses.

The Third Receptor: What Glucagon Agonism Adds

This is where retatrutide separates itself. It adds glucagon receptor agonism to the mix. At first, that sounds strange. Glucagon normally raises blood sugar, the opposite of what you want in a diabetes or weight loss drug.

But here is the key insight: when glucagon activates alongside GLP-1 and GIP, those hormones block its blood sugar effect. The GLP-1 component suppresses the glucagon-driven glucose rise. What you get instead are the metabolic benefits of glucagon activation without the glycaemic risk.

What Glucagon Receptor Activation Actually Does

1. Increases resting energy expenditure, your body burns more calories even at rest. 

2. Stimulates hepatic beta-oxidation; the liver actively burns stored fat cells (lipid droplets). 

3. Targets ectopic fat, deep organ fat in the liver, pancreas, and heart that dual agonists cannot reach. This is why retatrutide shows 86% hepatic fat normalisation in liver substudies. 

This compares with substantial, but lower, rates with tirzepatide. Tirzepatide reduces energy intake. It improves glycaemic control. This effect comes from GLP-1 and GIP receptor agonism.

Retatrutide also acts on GLP-1 and GIP receptors. In addition, it activates the glucagon receptor. Researchers have linked this to higher energy expenditure. It also affects lipid metabolism in clinical studies.

Efficacy Data: How Much Weight Do They Actually Cause You to Lose?

Tirzepatide: The Proven Results

Tirzepatide’s weight loss data comes from the SURMOUNT clinical trial programme. These are large, well-designed trials with thousands of participants.

• SURMOUNT-1 (obesity, no diabetes): 22.5% average weight loss at 72 weeks on the 15 mg dose
• SURMOUNT-2 (obesity + type 2 diabetes): 15.7% average weight loss at 72 weeks
• SURPASS trials (type 2 diabetes): HbA1c reduction of up to 2.3%, significant glycaemic control

These numbers were extraordinary at the time of approval. They were comparable to what bariatric surgery produced in some populations. No approved drug had achieved this level before.

Retatrutide: The Emerging Evidence

Retatrutide’s data comes from its Phase 2 trial.  The New England Journal of Medicine published the Phase 2 trial in 2023. 

It also includes the first Phase 3 result from the TRIUMPH-4 trial.

• Phase 2 (NEJM, 2023): 24.2% weight loss at 48 weeks on the highest dose
• Phase 3 TRIUMPH-4 (December 2025) reported results over 68 weeks. The 12 mg dose produced an average weight loss of 28.7%. 
• TRIUMPH-4 also showed: 58.6% of participants lost 25% or more of their body weight
• Average weight lost in TRIUMPH-4: 71.2 lbs (32.3 kg) from a baseline of approximately 248.5 lbs
• TRANSCEND-T2D-1 (March 2026, type 2 diabetes): Up to 16.8% weight loss + 2.0% HbA1c reduction at 40 weeks

The TRIUMPH-4 result is the highest metabolic loss figure ever recorded in a Phase 3 obesity trial. That 28.7% figure beats tirzepatide’s own registrational data from the same company.

Side Effects: What to Expect from Each Drug

Side Effects Both Drugs Share

Both retatrutide and tirzepatide belong to the same drug class. Because of this overlap in mechanisms, they also show many similar side effects. These are mostly gut-related and tend to appear during the dose ramp-up period.

• Feeling nauseous is the side effect reported most often with both medications. 
• Vomiting and diarrhoea occur in some patients, usually early on
• Constipation less common, but reported with both
• Reduced appetite and early fullness are technically the intended effects, but they can feel uncomfortable
• Delayed gastric emptying slows how fast food moves through your stomach; can affect how other oral medications are absorbed
• GLP-1 drugs carry a class-wide warning about thyroid C-cell tumours. 
• This warning applies to tirzepatide. 
• People also expect it to apply to retatrutide.

These side effects typically improve after 4 to 6 weeks as the body adjusts. Slow dose titration, starting low and increasing gradually, helps most patients tolerate treatment.

Side Effects Unique to Retatrutide

The glucagon receptor component in retatrutide creates some additional side effects that tirzepatide does not share:

• Increased resting heart rate glucagon receptor activation raises sympathetic nervous system activity. This is one of the main reasons retatrutide is still under investigation. Cardiac safety remains a key focus of ongoing TRIUMPH trials.
• Dysesthesia: abnormal skin sensations (tingling, numbness, or burning). Seen in 2.3% to 4.5% of participants in Phase 3 data. Not observed with tirzepatide.
• Minor blood sugar fluctuations can cause small glycaemic changes in some people.
• Some trial participants reported sleep disruption, likely because of elevated metabolic activity from glucagon agonism.

Safety Summary

Tirzepatide has multi-year real-world safety data and a well-characterised cardiac profile. Retatrutide’s Phase 3 cardiac outcomes trial (TRIUMPH-3) is still ongoing. Until that data is available, tirzepatide remains the safer choice for patients with heart concerns. Both drugs carry the standard GI side effect profile common to incretin-based therapies.

Availability, FDA Status, and Cost in 2026

Tirzepatide: Approved Dual Incretin Agonist

The U.S. Food and Drug Administration has approved tirzepatide, which Eli Lilly makes. 

It treats type 2 diabetes (Mounjaro, May 2022) and supports long-term weight management (Zepbound, November 2023). Many regions authorise it for clinical use. These include the United States, the European Union, and the United Kingdom.

Reported pricing varies by healthcare system and reimbursement structure. Public estimates in the United States indicate monthly costs exceeding $1,000, though values are variable.

Retatrutide: Investigational Triple Agonist (April 2026)

Retatrutide (LY3437943), developed by Eli Lilly, is still investigational. The U.S. Food and Drug Administration has not approved it as of April 2026. The TRIUMPH programme is currently conducting a Phase 3 evaluation.

Projected timelines may change.  Phase 3 may finish in 2026–2027.  Regulatory submission and review may follow.  Approval may happen in 2027–2028.

Research Access Context

Retatrutide is currently limited to controlled clinical research settings. Researchers continue to evaluate its safety and efficacy, and regulators have not authorised commercial distribution.

Beyond Weight Loss: Other Conditions Being Studied

Tirzepatide: Approved and Studied Indications

• Type 2 diabetes (Mounjaro), approved 2022
• Obesity/overweight (Zepbound), approved 2023
• Heart failure with preserved ejection fraction (HFpEF), Zepbound approved December 2024
• Obstructive sleep apnea, Zepbound approved June 2024
• Metabolic dysfunction-associated steatotic liver disease (MASLD), Phase 3 data positive

Retatrutide: Conditions Under Investigation

Eli Lilly is studying retatrutide across a wide range of conditions in its TRIUMPH, TRANSCEND, and SYNERGY trial programmes.

• Obesity + knee osteoarthritis (TRIUMPH-4): Phase 3 POSITIVE. 28.7% weight loss + 75.8% reduction in knee pain scores
• Type 2 diabetes (TRANSCEND-T2D-1): Phase 3 POSITIVE. 16.8% weight loss + 2.0% HbA1c reduction
• Obstructive sleep apnea (TRIUMPH-6): Phase 3 ongoing; results expected 2026
• Cardiovascular outcomes (TRIUMPH-3): Phase 3 ongoing; critical for cardiac safety profile
• MASLD / fatty liver disease (SYNERGY programme): Phase 3 is ongoing. 
• Phase 2 data showed 86% hepatic fat normalisation. 
• Glucagon receptor activity drove this by clearing liver fat.
• Chronic low back pain, Phase 3, ongoing

Which Drug Is Right for You?

Consider Tirzepatide If…

You want to start treatment today. You have type 2 diabetes and need an approved, well-studied option. You prefer a drug with years of real-world safety data behind it.

If you have cardiac concerns or a history of heart issues, tirzepatide has a more established cardiac profile. Your insurer covers GLP-1 or anti-obesity medications.

Consider Retatrutide If…

For the strongest weight-loss results seen in studies, you may consider joining a Phase 3 clinical trial. If you have significant fatty liver disease, the glucagon receptor mechanism may offer superior hepatic clearance.

You have obesity-related knee osteoarthritis. TRIUMPH-4 showed strong dual benefit for both weight and joint pain. Previous GLP-1 or dual incretin therapy did not give you enough results.

Note: Retatrutide is not available by standard prescription as of April 2026. You should make any decision about weight loss medication with your doctor or a specialist in metabolic medicine.

Frequently Asked Questions

The Bottom Line: Retatrutide vs Tirzepatide in 2026

Both drugs represent a massive leap forward in metabolic medicine. Both come from the same company, Eli Lilly. However, the two drugs are currently at markedly different stages of development. 

Tirzepatide is the proven, available option. FDA-approved, backed by years of real-world data, and accessible today by prescription. For most patients who want to start treatment now, it is the gold standard.

Retatrutide is the next step. Its triple agonism, adding glucagon receptor activation, gives it a mechanistic edge. The early Phase 3 data suggest it may deliver greater weight loss and better outcomes for fatty liver and joint disease. But they haven’t approved it yet.

The glucagon receptor is the key differentiator. It lets retatrutide target deep organ fat and raise resting energy use in ways dual agonists cannot match. If Phase 3 results stay strong, retatrutide could become the new standard drug treatment for obesity.

References & Data Sources

1. Eli Lilly (December 11, 2025). TRIUMPH-4 Phase 3 topline results. Lilly Investor Relations.

2. Jastreboff AM et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine, 389(6):514-526.

3. Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine.

4. Eli Lilly (March 19, 2026). TRANSCEND-T2D-1 Phase 3 topline results. Lilly Press Release. 5. FDA Drug Databases: Mounjaro (NDA 215866), Zepbound (NDA 217806). FDA.gov.